1. Home
  2. HOWL vs ARMP Comparison

HOWL vs ARMP Comparison

Compare HOWL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • ARMP
  • Stock Information
  • Founded
  • HOWL 2017
  • ARMP N/A
  • Country
  • HOWL United States
  • ARMP United States
  • Employees
  • HOWL N/A
  • ARMP N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HOWL Health Care
  • ARMP Health Care
  • Exchange
  • HOWL Nasdaq
  • ARMP Nasdaq
  • Market Cap
  • HOWL 87.4M
  • ARMP 80.0M
  • IPO Year
  • HOWL 2021
  • ARMP N/A
  • Fundamental
  • Price
  • HOWL $1.49
  • ARMP $1.95
  • Analyst Decision
  • HOWL Strong Buy
  • ARMP Strong Buy
  • Analyst Count
  • HOWL 2
  • ARMP 1
  • Target Price
  • HOWL $9.50
  • ARMP $7.00
  • AVG Volume (30 Days)
  • HOWL 261.8K
  • ARMP 7.9K
  • Earning Date
  • HOWL 03-06-2025
  • ARMP 03-20-2025
  • Dividend Yield
  • HOWL N/A
  • ARMP N/A
  • EPS Growth
  • HOWL N/A
  • ARMP N/A
  • EPS
  • HOWL N/A
  • ARMP N/A
  • Revenue
  • HOWL $3,386,000.00
  • ARMP $5,467,000.00
  • Revenue This Year
  • HOWL N/A
  • ARMP $23.87
  • Revenue Next Year
  • HOWL $34.17
  • ARMP N/A
  • P/E Ratio
  • HOWL N/A
  • ARMP N/A
  • Revenue Growth
  • HOWL N/A
  • ARMP 34.92
  • 52 Week Low
  • HOWL $1.26
  • ARMP $1.80
  • 52 Week High
  • HOWL $8.19
  • ARMP $4.48
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 54.09
  • ARMP 42.06
  • Support Level
  • HOWL $1.28
  • ARMP $1.89
  • Resistance Level
  • HOWL $1.60
  • ARMP $2.08
  • Average True Range (ATR)
  • HOWL 0.10
  • ARMP 0.10
  • MACD
  • HOWL 0.03
  • ARMP -0.01
  • Stochastic Oscillator
  • HOWL 67.65
  • ARMP 18.18

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: